{"id":50121,"date":"2025-01-31T16:00:35","date_gmt":"2025-01-31T16:00:35","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=50121"},"modified":"2025-02-21T15:44:39","modified_gmt":"2025-02-21T15:44:39","slug":"50121","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/50121","title":{"rendered":"EU license for injectable cabotegravir\/rilpivirine injections expanded to include adolescents >12 years old"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>On 31 January 2025, the European Commission extended the license for long-acting cabotegravir and rilpivirine to include adolescents aged 12 and over.<\/strong><\/p>\n<p>Individuals need to already be undetectable on their current ART, and to weigh &gt;35 kgs.<\/p>\n<p>The extension was supported by week 24 data in 144 adolescents from the ongoing phase1\/2 \u00a0IMPAACT 2017 MOCHA study, presented at CROI 2024. [2, 3]<\/p>\n<p>This open-label, non-comparative study reported that 139\/144 participants (96.5%) remained virologically suppressed &lt;50 copies\/mL with no new safety concerns. Nearly all participants expressed preference for the injections compared to oral ART.<\/p>\n<p>Reference<\/p>\n<ol>\n<li>ViiV Healthcare. European Commission authorises ViiV Healthcare\u2019s long-acting injectable cabotegravir + rilpivirine\u00a0for HIV treatment in adolescents. (31 January 2025).<br \/>\n<a href=\"https:\/\/viivhealthcare.com\/hiv-news-and-media\/news\/press-releases\/2025\/january\/long-acting-injectable-vocabria-rekambys-for-hiv-treatment\/\">viivhealthcare.com\/hiv-news-and-media\/news\/press-releases\/2025\/january\/long-acting-injectable-vocabria-rekambys-for-hiv-treatment\/<\/a><\/li>\n<li>Gaur A et al. Long-acting cabotegravir plus rilpivirine in adolescents with HIV: Week 24 IMPAACT 2017(MOCHA) Study. CROI 2024, abstract 188.<br \/>\n<a class=\"external\" href=\"https:\/\/www.croiconference.org\/abstract\/long-acting-cabotegravir-plus-rilpivirine-in-adolescents-with-hiv-week-24-impaact-2017mocha-study\/\" rel=\"noopener\">www.croiconference.org\/abstract\/long-acting-cabotegravir-plus-rilpivirine-in-adolescents-with-hiv-week-24-impaact-2017mocha-study\/<\/a><\/li>\n<li><span>Lowenthal ED et al. IMPAACT 2017 adolescent\/parent experiences with LA cabotegravir plus rilpivirine for HIV treatment. CROI 2024, abstract 949. Available at: <\/span><a class=\"text-wrap external\" href=\"https:\/\/www.croiconference.org\/abstract\/impaact-2017-adolescent-parent-experiences-with-la-cabotegravir-plus-rilpivirine-for-hiv-treatment\" rel=\"noopener noreferrer\">https:\/\/www.croiconference.org\/abstract\/impaact-2017-adolescent-parent-experiences-with-la-cabotegravir-plus-rilpivirine-for-hiv-treatment<\/a><span>.<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 31 January 2025, the European Commission extended the license for long-acting cabotegravir and rilpivirine to include adolescents aged 12 and over. Individuals need to already be undetectable on their current ART, and to weigh &gt;35 &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-50121","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/50121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=50121"}],"version-history":[{"count":8,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/50121\/revisions"}],"predecessor-version":[{"id":50141,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/50121\/revisions\/50141"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=50121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=50121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=50121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}